Novo Nordisk Cuts U.S. List Prices for Wegovy, Ozempic, Rybelsus

Novo Nordisk, the Danish pharmaceutical giant, announced on Tuesday that it will halve the U.S. list prices of its blockbuster weight loss drug Wegovy and cut prices on its diabetes treatments Ozempic and Rybelsus by about 35 percent, effective January 1, 2027. The changes aim to improve affordability for patients whose out-of-pocket costs are tied to list prices, such as those with high-deductible health plans or coinsurance requirements.

Under the new pricing, all three medications will carry a monthly list price of $675, down from Wegovy's current $1,349 and Ozempic and Rybelsus's $1,028. The reductions apply to all doses, including pill forms of Wegovy and Rybelsus. Company officials stated that the move reflects a commitment to enhancing access amid the complexities of the U.S. healthcare system, particularly for individuals in employer-sponsored plans where costs are calculated based on the list price before insurance discounts.

For many patients with commercial insurance, the actual cost remains low, often as little as $25 per month. The list price cuts do not affect direct-to-consumer or self-pay options, which Novo Nordisk has already lowered to attract cash-paying...